Accelerate the Progression of Safe and Effective Antigen Specific Immunotherapies
Through the Clinic, Optimize the Discovery of Novel Targets and Explore Novel Therapeutic Approaches Harnessing Combination Therapies

The 4th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 will be the only antigen-specific summit offering thought-leading content to drive the field towards a more precise and ethical antigen-specific approach to drug development.

This is the industry’s definitive antigen specific drug development forum.

Across 3 packed days, thought leaders from Novartis, ImCyse, Harvard Medical School, Toleranzia, Toralgen will reveal insight, data, and lessons learned from the last 12 months to enable you to hurdle the roadblocks preventing the development of clinically safe and effective antigen-specific immunotherapies for autoimmune and immune mediated disorders.

Expert Speakers Include

Charlotte Fribert

Chief Executive Officer

Toleranzia AB

Jean Van Rampelbergh

VP Clinical & Regulatory

Imcyse

Jose Carballido

Executive Director (Translational Medicine/ Preclinical Safety)

Novartis

Saso Cermerski

VP & Head of Discovery & Translation Immunology

Cue Biopharma

Why Attend the Digital ASIT 2021

Overcome the challenge of discovering and defining monogenic and multigenic antigens, optimize your tolerance delivery system by exploring POC data for different approaches to induce immune tolerance, confidently measure immune tolerance duration and determine clinical endpoints by discussing the application of novel clinical biomarkers.

Join 90+ of your peers looking to demonstrate clinical proof of concept for several therapeutic modalities including cell-based (CAR-Treg, TCR-Treg, tolAPCs), tolerogenic nanoparticles and therapeutic immunization, in a range of autoimmune and allergic conditions. The 4th annual ASIT Summit will ensure your antigen-specific immune tolerance research teams will return with the best industry practices for drug discovery, clinical programme design and formulating robust data for regulatory approvals.

Hear What Our Previous Attendees Have Said

"The most effective and engaging way to be up to speed on the progress in the field of antigen specific immunotherapy."
Assistant Professor, John Hopkins University

"The leading forum to gain a collective understanding of state-of-the-art practices in clinical development of ASIT."
Strategic Consultant, Gestalt Strategies

"Inspiring collection of world-class scientists and potential ground-breaking therapies."
Executive Director, Provention Bio Inc.